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1. Introduction 
1.1 Antimicrobial treatment: in desperate need of a wind of change 
 
“Without urgent, coordinated action by many stakeholders, the world is headed for a post-
antibiotic era, in which common infections and minor injuries which have been treatable for 
decades can once again kill” (1) 
      Dr Keiji Fukuda, WHO’s Assistant Director-General, Health Security.  
 
The increasing antibiotic resistance against commonly used antimicrobial agents is a 
worldwide threat, and has reached alarming levels.  Multidrug resistant bacteria cause the death 
of 25,000 Europeans each year, with an estimated burden on the healthcare system of € 1.5 
billion annually (2). According to a recent study published by the Centre for Disease Control 
(CDC) nearly half a million people in the United States are infected annually with the life-
threatening bacterium Clostridium difficile. Among these, at least 29.000 people died as a 
consequence of the infection (3). Despite the obvious urgent need for new antibiotics, the 
number of approvals is low (4). As the impact on public health and economics is tremendous, the 
World Health Organization (WHO) has made bacterial resistance one of its central focuses. Also, 
the WHO warned in its last global report that the 21th century can truly be the beginning of the 
‘post-antibiotic era’, a period in which people worldwide can die from common infections, 
because the available antibiotic treatments become ineffective, including the so-called “last 
resort” antibiotics (1). Obtaining a better understanding of the resistance mechanisms and the 
concomitant development of improved treatments are key for the future, as acknowledged in the 
May 2015 World Health Assembly action plan that attempts to manage the crisis globally (Box 
1.1) (5).  
 
  
Box 1.1: The WHO’s action plan to combat antimicrobial resistance                 (5) 
The goal of the WHO’s global action plan is on the one hand to prolong antibiotic treatments that are 
still successful in eradicating resistant bacteria, and on the other hand to decrease the number of 
emerging/existing resistant infections worldwide. Their strategy is essentially based on 5 cornerstones: 
  
1. More communication with different sectors (including healthcare, animal science, political 
authorities…) in order to increase awareness of the resistance problem 
2. Increase academic, industrial and economic research to maximize the knowledge about the incidence of 
antimicrobial resistance, related microorganisms, mechanisms of resistance development, effectiveness of 
existing and newly approaching treatments, cost of antimicrobial resistance… 
3. Reduce the amount of infections 
4. Limit misuse of antimicrobial agents 
5. Maximize the economic support to drug development, health care institutions, vaccine supply…  
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1.2 The biofilm lifestyle 
 
Intensive research has been conducted to obtain a better understanding of how bacteria 
become multiresistant to a range of antibiotics, and how this results in chronic, difficult to 
eradicate infections. In vitro and in vivo observations of persistent infections showed that 
bacteria are often organized as bacterial aggregates or biofilms, which contributes to a great 
extent to the problem of persistent infections (6). In these biofilms, the bacterial cells are packed 
together into dense large clusters, surrounded by a self-produced matrix of extracellular 
polymeric substances (EPS), including proteins, DNA and polysaccharides (7). These so-called 
sessile bacteria can communicate with each other in a highly organized fashion, which enables 
them to respond and adapt instantly to changing environmental conditions (8). Furthermore, 
the organized architecture of biofilms also acts as a protective barrier that protects biofilm 
bacteria from the host immune response (9).   
 
One of the typical properties of biofilms is their increased tolerance to antibiotic agents. 
They can withstand 10-1000 times higher antibiotic concentrations compared to their free-
floating planktonic counterparts (10). This raises the question on how to combat these bacterial 
biofilm-related infections. In order to find a solution to this pressing problem, one must unravel 
the precise mechanisms behind the increased biofilm tolerance. Distinction can be made 
between 4 distinct, but intertwined processes that lead to increased tolerance (10–12):  
 
1. The existence of different microenvironments within a biofilm, such as pockets of 
anaerobic regions or low pH due to local accumulation of acidic waste products, that 
may antagonize the action of antibiotics (13). 
2. The presence of a subpopulation of difficult to eradicate persister cells. 
3. The ability to counteract oxidative stress. 
4. The slow or incomplete penetration of antibiotics through biofilms. 
In this book chapter we will focus on the last tolerance mechanism. Limited mass 
transfer through biofilms is a recognized mechanism of tolerance and is caused by two main 
reasons. First, due to the fact that the bacterial cells are packed together in large dense cell 
clusters composed of hundreds or thousands of bacteria, they are more difficult to reach by 
antibiotics as compared to free-floating planktonic cells (14),(15). Second, the cells and cell 
clusters are surrounded by a sticky matrix, sometimes referred to as the “house of biofilm cells” 
(16). The biofilm matrix is a conglomeration of polysaccharides, proteins and extracellular DNA, 
providing strength and protection to the biofilm (17). Improving antibiotics penetration through 
biofilms is an important strategy to achieve a better treatment efficacy of both existing as well as 
potentially new antibiotics (Box 1.1).  
 
In this chapter, we will first look more closely into the structural organization of the 
bacterial biofilm in relation to hindered antibiotics penetration (Figure 1.1). Special attention 
will be given to the role of dense cell clusters, the sticky biofilm matrix and the presence of 
degrading enzymes (11,12,18). Next, we will explain different therapeutic approaches to 
improve antibiotics penetration through bacterial biofilms. Both physical methods to destruct 
the biofilm’s organization as the use of antibiotic-enclosing nanoparticles will be discussed. At 
the end of the chapter, the reader will have gained more insight into the different challenges that 
4 
 
antibiotics encounter while diffusing through bacterial biofilms, and will have become more 
acquainted with different strategies that are currently explored to overcome this problem.  
 
Insert Figure 1.1 here 
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2. How biofilms pose a challenge to the diffusion of antibiotics 
2.1 Mass transport phenomena in biofilms  
 
At first, biofilms were considered as simple systems of 4 planar layers lying on top of 
each other. These 4 layers were, from the bottom to the top, the substratum, the biofilm, the bulk 
liquid and a possible gas space (19). It was accepted that passive diffusion was the predominant 
mode of transport within biofilms. Only in the liquid bulk layer residing on top of the biofilm, 
convective flow could happen (20,21). With the introduction of confocal laser scanning 
microscopy (CLSM), this view on the structural organization of biofilms changed radically 
(22,23). Confocal microscopy enabled 3-D high-resolution imaging of biofilms (24), revealing 
their complex heterogeneous architectures (25). The bacterial cells were found to be organized 
in dense clusters of hundreds to even thousands of cells surrounded by a matrix of polymeric 
material that holds the cell aggregates together and contributes to the strength of the entire 
biofilm (9). CLSM also revealed that biofilms contain voids - open channels that run through the 
biofilm and are connected to the bulk liquid (26). Microscopic evaluation confirmed the 
possibility of liquid flow through these channels (27). In cell clusters, on the other hand, liquid 
flow was hindered, and became stagnant (27). Hence, two modes of mass transport are active 
inside biofilms. Inside the voids, both convection and diffusion are possible, whereas in the cell 
clusters diffusion is the principal mass transport mechanism (28). This was an important 
discovery, as the voids can transfer solutes quickly throughout the biofilm, but do not give direct 
access to the inner parts of the cell clusters (29).  
 
Because of the heterogeneity of biofilms and different penetration pathways (via voids 
and dense cell clusters), contradicting findings were published in literature regarding the 
existence of a diffusion barrier. Indeed, many studies state that antibiotics move fairly rapidly 
through biofilms (30–32), however, at the same time, also hindered penetration of antibiotics 
has been frequently observed, as described above (33–39). Confusion about the existence of a 
diffusion barrier is confounded by the way it is experimentally investigated. If the arrival of 
antibiotics at the base of the biofilm is taken as a measure for diffusion (29), often one will 
conclude that there is no diffusion barrier since antibiotics can reach those parts fairly easily 
through the large voids. However, this does not necessarily mean that the antibiotics have 
efficiently penetrated deep into the cell clusters (10). Another important issue is that it may not 
be sufficient to measure the arrival of antibiotics at a certain location in the biofilm. Also the rate 
of diffusion is an important aspect. It is possible that an antibiotic molecule is indeed 
transported through the biofilm, but that its rate of penetration is significantly reduced. When 
the sessile cells experience gradually increasing antibiotic concentrations instead of an 
immediate full antibiotic dose, they can have the time to mount a defensive response (40,41). 
Increased production of alginate has been reported by treating Pseudomonas aeruginosa biofilms 
with sub-inhibitory imipenem concentrations, hence resulting in a more viscous biofilm matrix 
(42). Sub-inhibitory concentrations of β-lactams increased colonic acid production in Escherichia 
coli biofilms, resulting in a more matured biofilm matrix (43).  
 
In conclusion, although limitation of mass transfer remains controversial, the 
controversy is inspired by differences in measurements, the complex structure of biofilms and 
the fact that it depends on the specific combination of biofilms and antibiotics (44). One can 
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safely conclude that a diffusion barrier can exist as evidenced by various studies for many 
antibiotics.  
2.2 Dense cell clusters 
 
To reach the cells in the deeper layers of the clusters, the antibiotics have to gradually 
diffuse through the narrow spaces in between the cells. A first question is whether there is a size 
limit for diffusion into the dense cell clusters.  
 
De Beer et al. examined the diffusion of three fluorescent dyes with different molecular 
weights in mixed biofilms of Klebsiella pneumoniae, Pseudomonas aeruginosa and Pseudomonas 
fluorescens (39,45). After microinjecting the dyes in the interstitial voids and cell clusters 
separately, fluorophore diffusion was analyzed. By evaluating how fast fluorophores can diffuse 
out of the initial spot, the local diffusion coefficient of the molecules could be measured in 
selected areas – rather than reporting an average diffusion coefficient for the entire biofilm. 
Fluorescein (MW 332) exhibited similar diffusion in the voids and in the cell clusters, whereas 
dyes of higher molecular weight such as TRITC-IgG (MW 150 000) and phycoerythrin (MW 240 
000) did not diffuse or were slowed down by 40% in the cell clusters, respectively. However, 
likely these findings are not caused by steric hindrance, but rather by binding interactions with 
biofilm constituents as penetration of TRITC-IgG was improved by adding bovine serum albumin 
(39,45). Indeed, in a recent study it was confirmed that nanoparticles up to around 100 nm can 
penetrate into dense biofilm clusters of Burkholderia multivorans and Pseudomonas aeruginosa 
virtually as efficient as small dextrans of 4 kDa (33). The authors used inert PEGylated 
polystyrene nanoparticles and liposomes ranging from 40 to 550 nm, which were visualized in 
their journey towards the biofilm cell clusters by confocal microscopy (Figure 2.1).  A general 
consensus about the optimal size of nanoparticles was obtained: particles smaller than 100-130 
nm are able to diffuse in the cell clusters, while penetration into the clusters was gradually less 
efficient for larger particles.   
 
Insert Figure 2.1 here 
 
This study confirms that the size of antibiotics is not likely to play a significant role in the 
diffusion into dense cell clusters (33). What does restrict net antibiotics influx into dense 
clusters is the fact that most of the cluster volume is occupied by the bacterial cells, while the 
space in between the cells through which the antibiotics have to diffuse constitutes only a minor 
volume fraction (Figure 2.2). This evidently limits the amount of antibiotics present within the 
clusters at any time, potentially leading to a suboptimal dose and ineffective treatment. In 
addition, as the antibiotics have to diffuse in between densely packed cells, the effective path 
length towards the cluster center is increased (29), further contributing to a delayed exposure of 
the deeper cell layers, which have more time to mount a defensive response.   
 
Insert Figure 2.2 here 
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2.3 Binding interactions between antibiotics and matrix constituents 
 
The second important characteristic of biofilms that contributes to their decreased 
diffusivity is their heterogeneous matrix that surrounds the cells and cell clusters. Antibiotic 
penetration in the biofilm can be substantially delayed or even inhibited by (transient) binding 
to matrix constituents (46). In addition, antibiotics may become inactivated by enzymatic 
degradation or modification.   
 
2.3.1 Physicochemical binding to matrix polymers 
 
It has been demonstrated in many studies that hindered diffusion can be the result of 
electrostatic interaction between antibiotic molecules and matrix polymers of opposite surface 
charge (46). For example, aminoglycosides such as tobramycin and gentamicin penetrate 
biofilms of mucoid Pseudomonas aeruginosa slower than β-lactam antibiotics (Figure 2.2). This is 
caused by the fact that the aminoglycosides, unlike β-lactams, can bind to extracellular polymers, 
such as alginates (34–37). Alginate is produced by mucoid Pseudomonas aeruginosa strains and 
is implicated in bacterial adhesion to substrates such as the respiratory epithelium (47). It is a 
copolymer consisting of (1,4)-linked-β-D-mannuronate and α-L-guluronate monomers which 
confers a negative charge to the polysaccharides (Figure 2.3) (48). Positively charged antibiotics, 
such as aminoglycosides, can bind to negatively charged alginate polymers by means of an 
electrostatic interaction.  
 
Insert Figure 2.3 here 
 
 
Recently, it has been found that not only mucoid strains offer protection against 
antibiotic penetration, but also the matrix in non-mucoid strains contains elements that retard 
antibiotic diffusion. Tseng et al. clearly demonstrated that, unlike the neutral fluoroquinolone 
ciprofloxacin, positively charged tobramycin was sequestered at the outer surface of non-
mucoid Pseudomonas aeruginosa biofilms. Therefore, it could not fully penetrate the biofilm 
anymore. To acquire information about which component of the matrix accounts for the 
tobramycin sequestration, different mutants of known EPS matrix components were examined.  
However, no polymers could be assigned as sequestering agents for tobramycin, because the 
penetration of tobramycin was similar in all biofilms. Further experiments showed that the 
tobramycin binding sites in the biofilm matrix could be saturated by adding high concentrations 
of either tobramycin or divalent cations. In both cases, the penetration of tobramycin was 
substantially increased, because ionic interactions with the matrix components were no longer 
possible (49). Billing et al. found that Psl, a known matrix component of non-mucoid 
Pseudomonas aeruginosa biofilms, was responsible for sequestering tobramycin. Psl was able to 
interact electrostatically with tobramycin, in this way contributing to the matrix barrier function 
of Pseudomonas aeruginosa biofilms (50,51). Finally, also Pel, the third known extracellular 
polysaccharide involved in Pseudomonas aeruginosa biofilm development - besides alginate and 
Psl –, has been reported to play a role in protecting Pseudomonas aeruginosa biofilms against 
aminoglycosides (52).  
 
Hindered penetration in biofilms has also been described for biocides (53). Chlorine, a 
biocide, is known to suffer from impaired penetration in biofilms (38). This was confirmed by 
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direct measurement of chlorine concentrations with microelectrodes in biofilms of Pseudomonas 
aeruginosa and Klebsiella pneumoniae; the chlorine concentration inside the clusters was not 
more than 20% of the incubation solution (38). A follow-up study revealed that biofilm 
constituents could trap chlorine in the periphery of the biofilm before it could diffuse inside the 
biofilm (54). Davison et al. measured that the time chlorine needed to fully penetrate a 
Staphylococcus epidermidis cluster was about 30min, while it would take ± 3s to diffuse if 
sorption did not occur (600x slower) (55). 
2.3.2 Inactivation of antibiotics by enzymes present in the biofilm matrix   
 
Degradative or modifying enzymes that are present in the biofilm matrix constitute yet 
another barrier to antibiotics in biofilms (12,46,56).   
 
Anderl et al. showed that the inability of ampicillin to eradicate wild-type K. pneumoniae 
biofilms was caused by enzymes in the biofilm surface layer degrading ampicillin before 
reaching the cells (Figure 2.4) (57). In β-lactamase deficient strains, ampicillin readily 
penetrated the biofilms, which supports the hypothesis that the penetration limitation is due to 
a reaction-diffusion barrier.   
 
Insert Figure 2.4 here 
 
Besides antibiotics, also biocides can be enzymatically inactivated in biofilms (53,58,59).  
Studies concerning the penetration of hydrogen peroxide into Pseudomonas aeruginosa biofilms 
revealed that penetration was largely retarded, likely by catalases (60). Catalases are enzymes 
that defend cells against oxidative stress by converting hydrogen peroxide into water and 
oxygen molecules (2H2O2  2 H2O + O2) (61). To test this assumption, H2O2 penetration was 
assessed in wild-type and catalase-deficient Pseudomonas aeruginosa biofilms. In the wild-type 
biofilms, H2O2 failed to fully penetrate the biofilm mass, as opposed to the catalase-deficient 
mutant biofilms, where H2O2 succeeded in penetrating the biofilm (60). Hence, catalase plays a 
role in protecting biofilm bacteria by decomposing H2O2 into its degradation products H2O and 
O2 in a reaction-diffusion mechanism (62).   
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3. How to improve antibiotic delivery to biofilm cells?  
 
In the previous section we have discussed the two factors that contribute to hindered 
diffusion of antibiotics in biofilms, i.e. reduced penetration in dense cell clusters and binding to 
matrix constituents. Consequently, improved antibiotics penetration could be achieved by either 
releasing the cells from their protective environment (63,64), or by shielding the antibiotics 
from interacting with matrix constituents (65,66). In the next sections we will discuss the 
various approaches that have been developed to this end.   
 
3.1 Interference with the biofilm structure 
 
 In order for antibiotics to more easily reach all cells in biofilms, cells could be released 
from their protective environment by interfering with the biofilm structure (35,67–72). Indeed, 
it has been observed in many studies that by degrading the biofilm structure, bacteria become 
more susceptible to antimicrobial treatment (71). An additional benefit is that releasing bacteria 
from their protective environment can also enhance recognition by polymorphonuclear 
leukocytes, aiding the immune system to clear the bacterial biofilm infection (73). Furthermore, 
degradation of the biofilm does not only increase antibiotic diffusion, but also the diffusion of 
nutrients, which activates the bacterial cells and renders them more susceptible for antibiotics 
(74).  
 
Interference with the biofilm structure can be achieved by specific compounds that 
degrade the biofilm matrix, for instance matrix dispersants that destabilize EPS or specific 
biofilm components such as eDNA (63,72). Messiaen et al. investigated the potential of NaClO 
and dispersin B to degrade the EPS matrix and the specific matrix component poly-β-1,6-N-
acetylglucosamine (PNAG) of Burkholderia cepacia biofilms, respectively (75). Destabilization of 
both compounds resulted in increased tobramycin susceptibility, confirming the fact that the 
EPS matrix plays a role in the tobramycin susceptibility of Burkholderia cepacia biofilms (75). 
Hatch et al. demonstrated the potential of alginate lyase in reducing the diffusion barrier of 
mucoid Pseudomonas aeruginosa biofilms to aminoglycosides (47). Alginate lyase enzymatically 
cleaves the glycosidic bounds of alginate by β-elimination (76). Degradation of the biofilm 
matrix by alginate lyase increased the diffusion of aminoglycosides into mucoid Pseudomonas 
aeruginosa biofilms and improved the aminoglycoside activity (47).  
 
Another way to interfere with biofilm formation is to target the bacterial communication 
system, called quorum sensing (QS). QS is the process in which bacteria release signaling 
molecules in a cell-density dependent manner, leading to altered gene expression. QS regulates 
different bacterial processes such as virulence, motility, biofilm formation, etc.… (77,78). 
Although more research needs to be performed to elucidate the precise role of QS in biofilm 
formation (79,80), many studies reported that quorum sensing inhibitors (QSI) can be a 
promising new class of antimicrobial agents that affect the biofilm’s structural organization 
(81,82). Davies et al. demonstrated that lasI mutants of Pseudomonas aeruginosa formed flat 
biofilms instead of the complex bacterial communities in case of wild-type biofilms. Moreover, 
the quorum-sensing mutants were also more susceptible to sodium dodecyl sulfate, 
demonstrating the potential of QSI’s in increasing the susceptibility of biofilms (83). Similar 
results were reported for Burkholderia cenocepacia (84), where QS-deficient mutants showed an 
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altered biofilm formation and increased sensitivity to sodium dodecyl sulfate (84). Brackman et 
al. investigated the potential of combining different antibiotics and QSI’s to affect the 
susceptibility of medically relevant biofilms. Both QSI’s targeting the acylhomoserine lactone-
based QS-system of Pseudomonas aeruginosa and Burkholderia cepacia, as the peptide-based 
system of Staphylococcus aureus, were investigated. They concluded that treating biofilms with 
QSI’s is promising for the eradication of bacterial biofilm infections, as the combined use of QSI’s 
and antibiotics resulted in increased killing efficiency (85).  
 
The disadvantage of using pharmacological compounds is that their specificity restricts 
broad applicability (86). Indeed, the biofilm matrix composition differs between various 
bacterial species and strains (87,88), and the presence of polymicrobial biofilms further 
increases the matrix heterogeneity (86,89). Physical approaches, on the other hand, that 
interfere with the biofilm structure could be more generally applicable.  
 
Many studies investigated the potential of ultrasonic waves to mechanically disrupt 
biofilms and consequently enhance antibiotic efficacy (90–94). Williams et al. showed that 
ultrasonic treatment of mucoid strains of Pseudomonas aeruginosa resulted in a significant 
decrease in alginate viscosity. Degradation of the mucoid polymer markedly increased the 
diffusion of tobramycin and piperacillin and consequently their efficacy (95). Another example is 
the use of low-frequency ultrasound to disrupt biofilms of Escherichia coli, which consequently 
enhances the efficacy of gentamycin in the eradication of the biofilm (96). Also, Dong et al. 
demonstrated the advantage of applying ultrasound (and ultrasound mediated microbubbles) in 
the treatment of Staphylococcus epidermidis biofilms, as ultrasound improved the penetration of 
vancomycin significantly (91). Furthermore, promising in vivo data were reported regarding the 
use of ultrasound for disrupting biofilm structures, such as in the treatment for chronic 
rhinosinusitis (97). Also, different in vivo studies reported that ultrasound could be used to 
disrupt biofilms of Escherichia coli, resulting in enhanced efficacy of aminoglycosides (98–100).  
Carmen et al. assessed the capability of low-frequency ultrasound to enhance the activity of 
vancomycin on the gram-positive bacterium Staphylococcus epidermidis. Biofilms were formed 
on polyethylene disks and implanted subcutaneously in rabbits. The combination of low-
frequency ultrasound and systemic vancomycin treatment reduced the number of viable 
bacteria, without causing detrimental tissue damage (101).  
 
Another example is the use of laser-generated shockwaves to physically disrupt biofilms.  
Efficient Staphylococcus epidermidis biofilm disruption was reported with the use of a Q-
switched ND:YAG laser (70). Nigri et al. demonstrated that the combination of laser-generated 
shockwaves with tobramycin could be used for efficient eradication of biofilms related to 
vascular prosthetic grafts. Shockwaves were generated in biofilms consisting of Staphylococcus 
epidermidis and Staphylococcus aureus, both isolated from vascular grafts. Subsequent 
tobramycin treatment resulted in a significant decrease in colony forming units, pointing out the 
potential of shockwaves to disrupt biofilm structures and to enhance the antibiotic’s efficiency 
(102).   
 
In conclusion, physical methods such as ultrasonic treatment have been successfully used to 
disrupt biofilms and release bacteria from their protective environment. Hence, the combination 
of physical biofilm disruption and concurrent antibiotic treatment is a promising route to 
explore in order to eradicate persistent biofilm infections (73,103).  
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3.2 Nanocarriers for improved delivery of antibiotics in biofilms  
3.2.1 Nanocarriers protect antibiotics from interactions with biofilm components 
 
Encapsulation of antibiotics inside nanomaterials reduces physicochemical interactions 
between biofilm matrix components and antimicrobial molecules (18,66,104–107). Hence, 
nanosized carriers can protect antibiotics from detrimental interactions with biofilm 
components (33). Meers et al. investigated if encapsulation of amikacin in DPPC:Chol liposomes 
could be beneficial in the treatment of chronic Pseudomonas aeruginosa biofilm infections. By 
CLSM it could be shown that those liposomes were able to penetrate Pseudomonas aeruginosa 
biofilms, resulting in a higher antibiotics concentration near the center of the biofilm as 
compared to the bulk fluid. Consequently, liposomal amikacin could reduce the bacterial count 
of Pseudomonas aeruginosa infections more than free amikacin (108,109). Mugabe et al. 
compared the activity of liposome-encapsulated gentamicin and free gentamicin against 
resistant strains of Pseudomonas aeruginosa isolates. DMPC:Chol, DPPC:Chol and DSPC:Chol 
liposomes encapsulating gentamicin exhibited a higher antimicrobial activity against 
Pseudomonas aeruginosa biofilms than gentamicin by itself. The authors attributed this effect to 
either an enhanced diffusion of the enclosed antibiotics through the biofilms, or protection 
provided by the liposomes against enzymatic degradation (110).  
Nanocarriers also offer protection against antibiotic degradation by detrimental enzymes 
that can be present in the biofilm matrix (65). Nacucchio et al. investigated if shielding 
piperacillin inside liposomes could offer protection against degradation by β-lactamases leading 
to improved bacterial efficacy. Therefore, both piperacillin containing 
phosphatidylcholine:cholesterol (1:1) liposomes and exogenous β-lactamase were added to 
Staphylococcus aureus biofilms and staphylococcal growth was examined. Non-encapsulated 
piperacillin was hydrolyzed by exogenous β-lactamases and resulted in similar Staphylococcus 
aureus growth as the control. Attaching piperacillin to the outside of (empty) liposomes 
provided protection against β-lactamases, as lower viability of Staphylococcus aureus was 
observed. This is thought to be due to steric hindrance for the enzymes. However, most 
successful protection was provided when piperacillin was encapsulated in the interior of the 
liposomes, resulting in the lowest staphylococcal growth of all conditions (111).  
Besides liposomal entrapment, encapsulation in polyacrylate nanoparticles has also been 
reported to protect antibiotics against enzymatic degradation. Turos et al. showed that 
nanoparticles loaded with penicillin exhibited increased antimicrobial activity against MRSA 
infections compared to free penicillin. Antimicrobial activity was even restored when exogenous 
β-lactamases were added, proving the fact that polymeric encapsulation can hide antibiotics 
against enzymatic attack by β-lactamases (112).  
3.2.2. Nanocarriers can be designed to increase local antibiotic delivery 
 
Besides size, surface charge and hydrophobicity are important for efficient delivery of 
NPs inside biofilms (113,114). For instance, Li et al. showed that anionic and neutral quantum 
dots could not penetrate E. coli biofilms, while cationic ones could (115). Furthermore, the 
authors demonstrated that hydrophobic cationic quantum dots could reach sessile cells, while 
more hydrophilic cationic quantum dots were bound to EPS matrix components. This shows 
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that, by rationally designing the NP outer surface through modifications of charge and 
hydrophobicity, nanoparticle-enclosed drugs can be targeted towards the EPS matrix (eg 
dispersing agents such as dispersin B) or bacterial aggregates (eg antimicrobial agents such as 
vancomycin) (115).  
By making use of charge-based attraction of NPs to biofilm constituents, nanometer-
sized delivery vehicles can reach parts in biofilms that are inaccessible to free antibiotics (114).  
Duncan et al. combined encapsulated peppermint oil and cinnamaldehyde with cationic silica 
NPs to treat bacterial biofilm infections (116). Self-assembly of the silica NPs at the oil-water 
phase resulted in capsules consisting of a core of peppermint oil and cinnamaldehyde and a shell 
of cationic NPs. Due to the penetration properties of the positive silica NPs, the capsules were 
able to diffuse into the entire biofilm, as visualized by confocal microscopy. Antimicrobial 
activity of the capsules was assessed against full-grown biofilms of Escherichia coli, Pseudomonas 
aeruginosa, methicillin-resistant Staphylococcus aureus and Enterobacter cloacae. It was found 
that viability significantly decreased with capsules carrying phytochemicals compared to free 
phytochemicals. Hence, transporting antimicrobial agents by nanometer-sized delivery vehicles 
directly to the biofilm-enclosed bacteria, greatly improved their therapeutic efficiency (116).   
Inclusion of certain lipids such as phosphatidylinositol (PI) or stearylamine (SA) can also 
be used to achieve interaction between phospholipid liposomes and specific compounds in the 
biofilm (117). The targeting potential of PI has been demonstrated to a variety of biofilm-
enclosed bacteria such as Streptococcus mutans, Streptococcus gordonii, Streptococcus sanguis, 
Proteus vulgaris, Staphylococcus epidermidis… (118–120). Attractive interactions are 
accomplished by forming hydrogen bonds between hydroxyl groups of inositol-molecules and 
polymers present on the bacterial surface (121). Stearylamine, on the other hand, can be used to 
achieve electrostatic interactions between positively charged SA-bearing liposomes and negative 
charges present in the bacterial biofilm (122). Stearylamine is known to guide liposomes to 
sessile bacteria such as Staphylococcus epidermidis, Staphylococcus aureus, and in a lower extent 
to Proteus vulgaris and oral bacteria such as Streptococcus mutans and Streptococcus sanguis 
(123,124). When comparing the affinity of PI:DPPC liposomes and DPPC-cholesterol-SA 
liposomes to Staphylococcus epidermidis biofilms, SA-liposomes possessed greater affinity for 
the bacteria (125). A possible explanation could be that hydrogen bonds originating from PI-
biofilm interactions are less efficient than the electrostatic interactions between SA-liposomes 
and negatively charged biofilm constituents (65).  
The possible disadvantage of using charge-based or hydrophobic interactions is the 
lower specificity, as most bacteria have a negative cell wall, accessible for electrostatic 
interactions, and matrix components, able to interact through hydrogen bonds (126). Indeed, to 
avoid detrimental side-effects, it is essential that antibiotics are directed to the pathogenic 
bacterial species (and/or strains), while they do not exert any bacteriostatic/bactericide effect 
on the commensal bacteria (127). Precise targeting of NPs to specific bacterial species and 
strains can be accomplished by functionalizing nanocarriers with targeting agents such as 
antibodies or lectins which interact with EPS and/or sessile bacteria (114). Highly specific 
targeting to Streptococcus oralis was accomplished by decorating DPPC:PI liposomes with 
antibodies raised to surface antigens of S. oralis. The immunoliposomes possessed high 
specificity to S. oralis, as little liposome adsorption was noticed around other oral bacteria like 
Streptococcus sanguis. For low chlorhexidine concentrations, targeted liposomal delivery 
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resulted in enhanced growth inhibition of S. oralis in comparison with non-encapsulated 
bactericides (128,129). Other site-directing molecules used to target NPs to bacterial biofilms 
include carbohydrate-binding lectins such as concanavalin A (con-A) and wheat germ agglutinin 
(WGA) (130,131). Con-A selectively targets α-D-mannopyranosyl and α-D-glucopyranosyl units, 
while WGA has a high specificity for N-acetylneuraminic acid and N-acetylglucosamine, present 
in peptidoglycan layer of bacterial cell walls and some lipopolysaccharides (132,133). Effective 
targeting to the carbohydrate receptors of Helicobacter pylori could be obtained by 
functionalizing gliadin nanoparticles with lectins, more specifically fucose-specific (UEA-I) and 
mannose-specific (Con A) lectins (134). WGA functionalized DPPC:DOTAP:NHS-PEG2000-
DSPE:mPEG2000-DSPE liposomes delivered more temoporfin to MRSA biofilms than unmodified 
liposomes or free temoporfin and resulted in complete eradication of the MRSA infection (133), 
highlighting the potential of targeted NPs to increase the antibiotic’s bioavailability and hence 
efficacy to bacterial biofilms.   
3.2.3 Nanocarriers can shuttle antibiotics inside bacterial cells 
 
Apart from a better delivery of antibiotics deep into biofilms, nanomaterials can also aid 
in improved delivery of antibiotics into cells. Gram-negative (and to a lower extent gram-
positive) bacterial cells are protected with multi-component barrier systems, restricting the 
permeation of antimicrobials (135,136). As the antibiotic targets are often located inside the cell 
(cytosol or cytoplasmic membrane) (137), cellular impermeability seriously decreases 
antibiotics efficiency (135,136). Therefore, nanocarriers – especially liposomes - that are 
designed to interact with cellular membranes, can be of paramount importance to increase 
antibiotic interaction with bacterial cells (138).  
The advantage of using liposomes as carriers for antibiotics, is that they are able to fuse 
with bacterial membranes, because the liposomal wall consists of amphiphatic phospholipids 
that resemble the cellular membrane. A particular class of liposomes, the so-called ‘fluidosomes’, 
deserve extra attention in this regard, as they have an enhanced capability to interact and fuse 
with phospholipid membranes (138). Fluidosomes consist of lipids, for example 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE) (139), that enhance the fluidity of nanocarriers. 
Mugabe et al. reported that liposomal entrapment of gentamicin increased the susceptibility of 
clinical isolates of Pseudomonas aeruginosa towards this antibiotic (110). Further investigation 
revealed that those fluidosomes guided the encapsulated aminoglycoside directly through the 
bacterial envelope, thereby avoiding the problem of restricted penetration through porin 
channels (140). Transmission Electron Microscopy images revealed a close interaction between 
DPPC:Chol liposomes encapsulating aminoglycosides such as amikacin, gentamicin or 
tobramycin and the cell membrane of Pseudomonas aeruginosa.  Liposome-bacterial membrane 
fusion was further evidenced by flow cytometry and lipid mixing studies (138,140).  
 Halwani et al. investigated the potential of fluidosomal encapsulation of different 
aminoglycosides in the treatment of Burholderia cenocepacia infections. Again, the same event 
was observed: fluidosomes were able to transfer aminoglycosides through the cell membrane of 
Burkholderia cenocepacia, thereby greatly increasing the efficiency of the antibiotics (141) . 
Insert Figure 3.1 here 
Beaulac et al. investigated the suitability of fluidosomes against a wide range of 
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pathogens including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Burkholderia 
cepacia, Escherichia coli and Staphylococcus aureus (142). Liposomes consisting of 
dipalmitoylphosphatidylcholine (DPPC) and dimyristoylphosphatidylglycerol (DMPG) were 
loaded with subinhibitory-concentrations of tobramycin and, surprisingly, possessed strong 
bactericidal activity against all strains; the same but non-encapsulated amount of tobramycin 
(only 50% of the tobramycin MIC) could not exert this effect (142). It was shown by negative 
staining that fluidosomes interacted closely with the bacterial outer membrane (Figure 3.1).  
Immuno-electron microcoscopy images showed that more tobramycin could penetrate the 
bacterial cells in case of fluidosomal entrapment than in case of free tobramycin. Integration of 
fluidosomal phospholipids in bacterial membranes could be confirmed by Fluorescence 
Activated Cell Sorting. After fusion, the fluorescent lipophilic marker PKH-2GL was detected in 
bacterial cells, proving that fluidosomal phospholids were integrated in bacterial walls (143).  
In vivo experiments confirmed the potential of fluidosomes in the treatment of bacterial 
infections. DPPC:DMPG liposomes containing tobramycin were tested in an in vivo rat model by 
infecting the rats with a mucoid strain of Pseudomonas aeruginosa. The fluidity of the liposomal 
wall was important, as only fluid DPPC:DMPG liposomes (transition phase temperature around 
30°C) eradicated the pulmonary mucoid Pseudomonas aeruginosa infection. Both tobramycin 
loaded rigid liposomes (transition phase temperature around 40°C), as free tobramycin, were 
not effective in treating the Pseudomonas auruginosa infection, highlighting the importance of 
the liposomal wall fluidity for optimal fusion with bacterial membranes (144).  
 
3.2.4 Responsive nanoparticles: antibiotic release on demand 
 
As mentioned in the previous section, nanocarriers can be designed to shuttle antibiotics 
directly into the bacterial cells, thus greatly improving their cytosolic delivery. In other cases, it 
is more favourable to deliver agents in the proximity of the bacterial cell, rather than 
intracellularly, eg in case of DNase that degrades extracellular DNA (145). To this end, 
nanocarriers can be functionalized with responsive moieties that enable triggered release of the 
antibiotic, once the carrier reaches the target site (146).  
 
Many studies were conducted to investigate different triggers for antibiotic release from 
nanocarriers such as liposomes and polymeric NPs (147–150). Both internal triggers such as 
enzymes and pH variations, as external factors such as light, heat and ultrasound can be used to 
release drugs out of carriers. A comprehensive discussion of this subject is beyond the scope of 
this chapter and therefore we want to refer the reader to recent reviews on this topic (151,152).  
We would like to highlight one trigger mechanism that selectively activated nanocarriers at the 
bacterial biofilm site, the so-called ‘microbial responsive nanocarriers’. It has been 
demonstrated that rhamnolipids, a certain type of virulence factor of Pseudomonas aeruginosa, 
could disturb the liposomal membrane, in this way selectively releasing amikacin out of the 
liposomes at the microbial infection site (108,153). Rhamnolipids were able to trigger release of 
amikacin from DPPC:cholesterol liposomes in a very efficient way: one rhamnolipid molecule 
per 100 lipids present in liposomes was sufficient to lead to amikacin release (108).  
 
Another example of microbial responsive nanocarriers is the release of gentamicin out of 
polymer nanocarriers in contaminated wounds. It has been shown that fluids from 
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Staphylococcus aureus-infected wounds contained thrombin-like molecules, capable of 
destabilizing thrombin-sensitive linkers that conjugated gentamicin on polymer nanoparticles 
(154). A third example is the release of vancomycin out of AuNP functionalized liposomes by α-
toxins secreted by Staphylococcus aureus. Αlpha-toxins are known for their pore-forming 
abilities in membranes, and can be used to disrupt liposomal membranes for antibiotic release 
(155).  
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4. Conclusion 
 
With multiresistant bacteria emerging worldwide and the shortage of novel antibiotics in the 
development pipeline, novel approaches for antimicrobial treatment are required. Making use of 
existing antibiotic molecules, but increasing their delivery towards biofilm cells, is a very 
promising route to follow. Disrupting biofilms, by enzymatic degradation as well as physical 
methods, has been shown to greatly enhance antibiotic’s efficacy. However, more research 
should be performed in order to translate these concepts into clinical settings. On the other 
hand, the potential of nanoparticle-assisted antibiotic delivery has been assessed by many 
studies, and promising results paved the way for intense worldwide investigation. To achieve 
maximal output, smart engineering of the NP is essential: NP size, surface charge, chemical 
composition, attachment of site-directing molecules and responsive linkers are crucial in 
obtaining elevated antibiotic delivery. Further research should take into account those factors 
and assess the biofilm penetration ability of the carriers with advanced microscopy techniques 
such as Single Particle Tracking and Fluorescence Correlation Spectroscopy. Furthermore, more 
research should focus on the construction of NPs that effectively target biofilm-enclosed cells, 
while at the same time avoiding interactions with tissues distributed throughout the entire 
human body. Instead of charge-based interactions, which will not exclusively occur at the 
biofilm, one should screen for specific targeting agents, directed against precise bacterial 
determinants, while considering that higher specificity is often accompanied with lower affinity. 
Also, as the majority of published papers include in vitro data only, assessment of the toxicity 
and applicability in vivo is urgently needed. In conclusion, rationally designed antibiotic-
enclosing NPs have potential to increase antibiotic delivery, and could be useful in the future 
treatment of infectious diseases. 
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Figure legends 
Figure 1.1 Schematic representation of the architecture of bacterial biofilms and different 
approaches to improve antibiotic penetration.  
Left: Two important features of biofilms contribute to their limited diffusivity to antimicrobial 
agents. First, cells are packed into dense cell clusters, due to which antibiotics cannot easily 
reach deep cell layers. Second, sessile cells are surrounded by a biofilm matrix that can hinder 
antibiotic diffusion, due to physicochemical interactions of antibiotics with matrix constituents. 
Right: Improved antibiotic penetration can essentially be obtained by two therapeutic 
approaches. One the one hand, the biofilm structure can be degraded in order to release cells 
from their protective environment. On the other hand, antibitiotics can be shielded from 
interactions with biofilm matrix constituents by encapsulation in nanocarriers. 
 
Figure 2.1: The percentage of penetrated polystyrene nanoparticles (open), liposomes (dashed) 
and control molecules (FITC-dextran 4000 Da, grey) in Burkholderia multivorans LMG18825 
(left) and Pseudomonas aeruginosa LMG27622 biofilms (right) (33). 
 
Figure 2.2: Restricted antibiotic diffusion into dense cell clusters of bacterial biofilms.    
 
Figure 2.3: Structure of aminoglycosides gentamicin, tobramycin and the polysaccharide 
alginate.  
 
Figure 2.4: Structure of ampicillin, with the characteristic β-lactam ring.  
 
Figure 3.1: Electron microscopy image of the interaction between fluidosomes and Pseudomonas 
aeruginosa 429 by negative staining with 1% phosphotungstenic acid. Fluidosomes came in 
close contact with the bacterial cell membrane and eventually fusion took place (enlargement of 
the outer membrane) (143).  
 
 
 
 
 
